The Race To Keep Antibody Treatments One Step Ahead Of Covid-19 Variants

The Race To Keep Antibody Treatments One Step Ahead Of Covid-19 Variants
Share to Facebook
Share to Linkedin
Scientists working on the development of human monoclonal antibodies against coronavirus (Photo by Gianluca Panella/Getty Images)
Getty Images
Antibody therapies have been a key tool in keeping patients out of hospitals, but drug companies are fighting to stay ahead of coronavirus mutations.
Last year, as the Covid-19 pandemic raged across the country, filling hospitals beyond capacity, biotech companies raced to develop new treatments and vaccines. Pharma company Eli Lilly, for example, partnered with Vancouver-based AbCellera to develop an antibody treatment. That partnership began in February 2020, and by May the new drug,  bamlanivimab was already in clinical trials. Six months later, in November, the company received an emergency use authorization from  the FDA, and the Federal government contracted for 950,000 doses of the treatment at a price of $1.2 billion.  

Related Keywords

South Africa ,California ,United States ,South African ,Daniel Skovronsky ,Eli Lilly ,Sean Liu ,Glaxosmithkline ,Regeneron Pharmaceuticals ,Milken Institute Fastercures ,Vancouver Based Abcellera ,Christos Kyratsous ,Mount Sinai ,Covid Clinical Trials ,Chief Science Officer Daniel Skovronsky ,San Francisco Based ,Vir Biotechnology ,Amanda Peppercorn ,Milken Institute ,Vaccine Companies Are Battling ,Fda ,Us ,Antibody ,Covid 19 ,Therapy ,Pharma ,Pharmaceutical ,Treatment ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,எலி லில்லி ,சீன் லியூ ,கிளாக்சோஸ்மித்க்லைன் ,வான்கூவர் அடிப்படையிலானது ,ஏற்ற சினை ,சான் பிரான்சிஸ்கோ அடிப்படையிலானது ,வீர் உயிரி தொழில்நுட்பவியல் ,அமண்டா மிளகுத்தூள் ,பால் நிறுவனம் ,ஃப்ட ,எங்களுக்கு ,ஆன்டிபாடி ,சிகிச்சை ,பார்மா ,மருந்து ,